A third vaccination with a single T cell epitope protects against SARS-CoV-2 infection in the absence of neutralizing antibodies
Pardieck, I. N.; van der Gracht, E. T. I.; Veerkamp, D. M. B.; Behr, F. M.; van Duikeren, S.; Beyrend, G.; Rip, J.; Nadafi, R.; van der Sluis, T. C.; Beyranvand Nejad, E.; Mulling, N.; Brasem, D. J.; Camps, M. G. M.; Myeni, S. K.; Bredenbeek, P. J.; Kikkert, M.; Kim, Y.; Cicin-Sain, L.; Abdelaal, T.; van Gisbergen, K. P. J. M.; Franken, K. L. M. C.; Drijfhout, J. W.; Melief, C. J. M.; Zondag, G. C. M.; Ossendorp, F.; Arens, R.
Show abstract
Understanding the mechanisms and impact of booster vaccinations can facilitate decisions on vaccination programmes. This study shows that three doses of the same synthetic peptide vaccine eliciting an exclusive CD8+ T cell response against one SARS-CoV-2 Spike epitope protected all mice against lethal SARS-CoV-2 infection in the K18-hACE2 transgenic mouse model in the absence of neutralizing antibodies, while only a second vaccination with this T cell vaccine was insufficient to provide protection. The third vaccine dose of the single T cell epitope peptide resulted in superior generation of effector-memory T cells in the circulation and tissue-resident memory T (TRM) cells, and these tertiary vaccine-specific CD8+ T cells were characterized by enhanced polyfunctional cytokine production. Moreover, fate mapping showed that a substantial fraction of the tertiary effector-memory CD8+ T cells developed from remigrated TRM cells. Thus, repeated booster vaccinations quantitatively and qualitatively improve the CD8+ T cell response leading to protection against otherwise lethal SARS-CoV-2 infection. SummaryA third dose with a single T cell epitope-vaccine promotes a strong increase in tissue-resident memory CD8+ T cells and fully protects against SARS-CoV-2 infection, while single B cell epitope-eliciting vaccines are unable to provide protection.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin 97%
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization 97%
- Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA Vaccine 96%
Similar papers in this journal
Similar papers in this journal
- A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses 98%
- Heterologous immunization modulates B-cell epitope competition between helper peptides and the MPER segment in MPER/liposome vaccines 97%
- Durability of DNA-LNP and mRNA-LNP Vaccine-Induced Immunity Against SARS-CoV-2 XBB.1.5 96%
Similar papers in this journal
- Memory B cell Development in Response to mRNA SARS-CoV-2 and Nanoparticle Immunization in Mice 96%
- Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques 96%
- Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination 96%
Similar papers in this journal
- Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2 96%
- Preexisting memory CD4 T cells in nÏave individuals confer robust immunity upon hepatitis B vaccination 95%
- Early acquisition of S-specific Tfh clonotypes after SARS-CoV-2 vaccination is associated with the longevity of anti-S antibodies 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.